PCSK9 protein, human
Eli Lilly Pays $1B Upfront to Acquire Verve Therapeutics, Expanding Cardiovascular Gene Editing Portfolio
Eli Lilly; Verve Therapeutics; gene editing; cardiovascular disease; acquisition; PCSK9; VERVE-102; biotech; heart disease
Actionable Insights Powered by AI
Eli Lilly; Verve Therapeutics; gene editing; cardiovascular disease; acquisition; PCSK9; VERVE-102; biotech; heart disease